EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Computational Design and Glycoengineering of Interferon‐Lambda for Nasal Prophylaxis Against Respiratory Viruses

Jeongwon Yun iD, Seungju Yang iD, Jae Hyuk Kwon iD, Luiz Felipe Vecchietti iD, Ji Hyun Choi iD, Mi-Ra Choi iD, Keun Bon Ku iD, Hyun-Joo Ro iD, Kyun-Do Kim iD, Meeyoung Cha iD, Hyun Jung Chung iD, Ji Eun Oh iD und 1 weitere

Advanced Science · 2026

DOI: 10.1002/advs.202506764 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Jeongwon Yun und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 34141, Republic of Korea. Hauptthemen laut MEDLINE: Antiviral Agents, Interferons, Respiratory Tract Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institute for Basic Science, National Research Foundation of Korea, Korea Health Industry Development Institute (KHIDI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interferon‐λ (IFN‐λ), a type III interferon that selectively targets epithelial cells, holds strong potential as an intranasal antiviral due to its ability to suppress respiratory virus replication without inducing systemic inflammation. However, clinical translation of human IFN‐λ3 (hIFN‐λ3) is hindered by limited thermostability, protease susceptibility, and rapid mucosal clearance. In this study, instability‐prone elements in hIFN‐λ3 are eliminated through artificial intelligence (AI)‐based backbone remodeling and targeted surface hydrophobic patch engineering. A protease‐sensitive loop is replaced with a de novo α‐helix, which shields neighboring hydrophobic patches and forms a new hydrophobic core, yielding an engineered variant (hIFN‐λ3‐DE1) with enhanced thermostability (Tm > 90 °C), protease resistance, and preserved antiviral activity and structural integrity even after extended heat stress (two weeks at 50 °C). Further glyco‐engineering introduces an N‐linked glycan at a site distant from receptor‐binding interfaces, improving solubility, production yield, and diffusion through synthetic nasal mucus. Intranasal administration of the resulting variant (G‐hIFN‐λ3‐DE1) enables effective mucosal penetration and provides a more rapid onset of in vivo prophylactic protection against influenza A virus. These findings highlight a robust and versatile strategy that combines AI‐driven structural design with glyco‐engineering to develop scalable, bioavailable, and functionally enhanced nasal biologics for respiratory virus prophylaxis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsInterferonsRespiratory Tract InfectionsHumansAdministration, IntranasalAnimalsProtein EngineeringMiceInterferon LambdaInterleukins

Stichwörter der Autor:innen

AI‐based protein designGlyco‐engineeringantiviral prophylaxisinterferon‐lambdaintranasal biologics

Substanzen

Antiviral AgentsInterferonsInterferon Lambdainterferon-lambda, humanInterleukins

Autor:innen und Institutionen

  • Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 34141, Republic of Korea.
  • InnoCORE AI-CRED Institute, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 34141, Republic of Korea.
  • Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 34051, Republic of Korea.
  • Max Plank Institute for Security and Privacy (MPI-SP), 44799, Bochum, Germany.
  • Center for Infectious Disease Vaccine and Diagnosis Innovation (CEVI), Korea Research Institute of Chemical Technology, Daejeon, 34114, Republic of Korea.
  • Center for Biomolecular and Cellular Structure, Institute for Basic Science (IBS), Daejeon, 34126, Republic of Korea.

ORCID-Profile: Jeongwon Yun, Seungju Yang, Jae Hyuk Kwon, Luiz Felipe Vecchietti, Ji Hyun Choi, Mi-Ra Choi, Keun Bon Ku, Hyun-Joo Ro, Kyun-Do Kim, Meeyoung Cha, Hyun Jung Chung, Ji Eun Oh, Ho Min Kim

Förderung

  • Institute for Basic Science
  • National Research Foundation of Korea
  • Korea Health Industry Development Institute (KHIDI)
  • Korea Advanced Institute of Science and Technology (KAIST): Convergence Research Institute Operation Program
  • Ministry of Science and ICT (South Korea) (MIST): N10250153 (InnoCORE program)

Zitieren

APA

Yun, J., Yang, S., Kwon, J. H., Vecchietti, L. F., Choi, J. H., Choi, M. R., Ku, K. B., Ro, H. J., Kim, K. D., Cha, M., Chung, H. J., Oh, J. E., & Kim, H. M. (2026). Computational Design and Glycoengineering of Interferon‐Lambda for Nasal Prophylaxis Against Respiratory Viruses. Advanced Science. https://doi.org/10.1002/advs.202506764

Vancouver

Yun J, Yang S, Kwon JH, Vecchietti LF, Choi JH, Choi MR, et al. Computational Design and Glycoengineering of Interferon‐Lambda for Nasal Prophylaxis Against Respiratory Viruses. Advanced Science. 2026. doi:10.1002/advs.202506764

BibTeX
@article{Yun2026,
  author = {Yun, Jeongwon and Yang, Seungju and Kwon, Jae Hyuk and Vecchietti, Luiz Felipe and Choi, Ji Hyun and Choi, Mi-Ra and Ku, Keun Bon and Ro, Hyun-Joo and Kim, Kyun-Do and Cha, Meeyoung and Chung, Hyun Jung and Oh, Ji Eun and Kim, Ho Min},
  title = {Computational Design and Glycoengineering of Interferon‐Lambda for Nasal Prophylaxis Against Respiratory Viruses},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.202506764}
}
Kostenlos starten →